Published in Tech Urol on March 01, 2000
Noninvasive urodynamic evaluation of bladder outlet obstruction using Doppler ultrasonography. Urology (2000) 1.54
Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol (2001) 1.54
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.45
Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J Urol (1999) 1.41
Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol (1985) 1.35
The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2003) 1.32
Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol (1999) 1.32
Bladder and sphincter behavior in patients with spinal cord lesions. J Urol (1991) 1.28
Urodynamics of spinal cord injury. Urol Clin North Am (1996) 1.25
The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol (2001) 1.19
Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol (2001) 1.18
Neural control of the urethra. Scand J Urol Nephrol Suppl (2001) 1.17
Development of noninvasive velocity flow video urodynamics using Doppler sonography. Part II: clinical application in bladder outlet obstruction. J Urol (1998) 1.16
Development of noninvasive velocity flow video urodynamics using Doppler sonography. Part I: Experimental urethra. J Urol (1998) 1.11
The involvement of the tetrodotoxin-resistant sodium channel Na(v)1.8 (PN3/SNS) in a rat model of visceral pain. J Neurosci (2001) 1.11
Early predictors of bladder recovery and urodynamics after spinal cord injury. Neurourol Urodyn (1998) 1.09
Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. J Urol (2000) 1.06
Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol (2000) 1.05
Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther (2002) 1.04
Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. Am J Physiol Regul Integr Comp Physiol (2001) 1.02
Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol (2001) 1.01
Changes in micturition after spinal cord injury in conscious rats. Urology (1999) 1.00
Molecular marker for development of interstitial cystitis in rat model: isoactin gene expression. J Urol (1997) 0.98
Myoblast therapy for stress urinary incontinence and bladder dysfunction. World J Urol (2000) 0.97
Modified Burch colposuspension for stress urinary incontinence in females. Surg Gynecol Obstet (1993) 0.95
Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int (2003) 0.95
A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol (1984) 0.95
Effects of cigarette smoke components on in vitro chemotaxis of human polymorphonuclear leukocytes. Infect Immun (1977) 0.94
Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol (2001) 0.93
Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology (2001) 0.93
Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord (2000) 0.93
Influence of glutamate receptor antagonists on micturition in rats with spinal cord injury. Exp Neurol (1999) 0.92
The effect of urinary tract reconstruction on neurologically impaired women previously treated with an indwelling urethral catheter. J Urol (1996) 0.92
Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. J Urol (2001) 0.91
Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther (2009) 0.91
Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech Urol (2001) 0.91
Injection of skeletal muscle-derived cells into the penis improves erectile function. Int J Impot Res (2005) 0.91
Muscle-derived cell transplantation and differentiation into lower urinary tract smooth muscle. Urology (2001) 0.90
Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets. J Immunol (1985) 0.90
Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther (2008) 0.89
Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther (2007) 0.89
Lyme cystitis and neurogenic bladder dysfunction. Lancet (1992) 0.86
High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. J Urol (1998) 0.86
Reliability of color Doppler ultrasound urodynamics in the evaluation of bladder outlet obstruction. Urology (2000) 0.86
Spinal cord injury and bladder recovery. Arch Phys Med Rehabil (1996) 0.85
Pharmacologic and potential biologic interventions to restore bladder function after spinal cord injury. Curr Opin Neurol (2000) 0.85
Laparoscopic-assisted continent urinary diversion in obese patients. J Endourol (1999) 0.85
Autologous primary muscle-derived cells transfer into the lower urinary tract. Tissue Eng (2001) 0.85
Complications of Teflon injection for stress urinary incontinence. Neurourol Urodyn (1993) 0.83
Expression of B cell activation antigens on normal and malignant B cells. Leukemia (1987) 0.83
31-Year-old bladder diverticulocutaneous fistula with a giant stone as a complication of pelvic fracture. Tech Urol (2001) 0.83
Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch Phys Med Rehabil (1995) 0.83
Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up. Tech Urol (1999) 0.83
Advantages and risks of ileovesicostomy for the management of neuropathic bladder. Urology (1999) 0.82
Latex allergy manifested in urological surgery and care of adult spinal cord injured patients. Arch Phys Med Rehabil (1994) 0.82
The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group. Urology (1994) 0.82
A reliable, nondestructive animal model for interstitial cystitis: intravesical low-dose protamine sulfate combined with physiological concentrations of potassium chloride. Urology (2001) 0.82
Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct (2002) 0.81
Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol (2000) 0.81
Erectile response to topical, intraurethral and intracorporal pharmacotherapy in a rat model of spinal cord injury. J Spinal Cord Med (1995) 0.81
Cutaneous ileocystostomy (a bladder chimney) for the treatment of severe neurogenic vesical dysfunction. Paraplegia (1995) 0.80
Stem cell therapy for urethral sphincter regeneration. Minerva Urol Nefrol (2008) 0.80
Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. Neurourol Urodyn (2001) 0.80
Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adenovirus-transduced myoblast vectors. Mol Urol (2001) 0.80
Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents. Neurourol Urodyn (1995) 0.79
Urolume stent placement for the treatment of postbrachytherapy bladder outlet obstruction. Urology (2000) 0.79
Neurological manifestations of baclofen withdrawal. J Urol (1993) 0.79
Mapping the future for incontinence treatment worldwide: highlights from the first international consultation on incontinence june 28-july 1, 1998, monaco. Rev Urol (1999) 0.79
Epidemiology of current treatment for sexual dysfunction in spinal cord injured men in the USA model spinal cord injury centers. J Spinal Cord Med (1996) 0.78
Variations in the gingival polymorphonuclear leukocyte migration rate in dogs induced by chemotactic autologous serum and migration inhibitor from tobacco smoke. J Periodontal Res (1977) 0.78
Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther (2009) 0.78
Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells. Int Urol Nephrol (2014) 0.78
Flexible cystoscopy in spinal cord injury. Review article. Paraplegia (1994) 0.78
Detrusor-myoplasty to restore micturition. Lancet (1994) 0.78
[Pittsburgh experience with botulinum toxin A injection]. Actas Urol Esp (2006) 0.77
Medical and minimally invasive treatment of urinary incontinence. Rev Urol (1999) 0.77
Evaluation of autologous fat implantation in the rat urinary bladder submucosa. Urology (1998) 0.77
Effect of intravesical capsaicin and vehicle on bladder integrity control and spinal cord injured rats. J Urol (1998) 0.77
Suppression of the tetrodotoxin-resistant sodium channel (PN3/SNS): a possible new treatment for bladder pain. Urology (2001) 0.77
Gracilis muscle dynamic urethral sphincter myoplasty: rat model experience. J Urol (1996) 0.77
Prospective comparison of external sphincter prosthesis placement and external sphincterotomy in men with spinal cord injury. J Endourol (1994) 0.76
Neurovesical dysfunction in postural tachycardia syndrome (POTS). Int Urogynecol J Pelvic Floor Dysfunct (2002) 0.76
Malignant priapism as the initial clinical manifestation of metastatic renal cell carcinoma with invasion of both corpora cavernosum and spongiosum. Int J Impot Res (1998) 0.76
Botulinum-A toxin: an exciting new treatment option for prostatic disease. Int J Clin Pract Suppl (2006) 0.76
Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia (1994) 0.76
Intravesical capsaicin in neurologic impaired patients with detrusor hyperreflexia. J Spinal Cord Med (1996) 0.76
Urologic manifestation of spinal cord sarcoidosis. J Spinal Cord Med (1996) 0.76
Neurogenic vesical dysfunction. Urol Clin North Am (1995) 0.76
Future trends in the treatment of urinary incontinence. Rev Urol (2001) 0.76
Bladder autoaugmentation. Tech Urol (1995) 0.76
First-line therapy for stress incontinence. Rev Urol (2000) 0.75
Should I do a pubovaginal sling operation on an obese woman? Rev Urol (2000) 0.75
Should we be using chili pepper extracts to treat the overactive bladder? J Urol (1997) 0.75
Stress urinary incontinence. Rev Urol (2000) 0.75
What is the best way to treat incontinence: behavioral or drug treatment? Rev Urol (2000) 0.75
Managing stress incontinence and classifying detrusor instability. Rev Urol (1999) 0.75
Managing incontinence: the tip of the iceberg. Rev Urol (1999) 0.75